Preventable Hospital Admissions Related to Medication (HARM): Cost analysis of the HARM study

Value in Health

Volumn 14, Issue 1, 2011, Pages 34-40

  Leendertse, Anne J ^a,b   Van Den Bemt, Patricia M L A ^a,c   Bart Poolman, J ^d   Stoker, Lennart J ^e   Egberts, Antoine C G ^a,b   Postma, Maarten J ^d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e Altrecht Institute for Mental Healthcare   (Netherlands)

Author keywords

Adverse drug event; Direct costs; Health care costs; Pharmacy; Productivity costs

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL ADMISSION RELATED TO MEDICATION; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; INCIDENCE; PREVENTION STUDY; PRIORITY JOURNAL; PRODUCTIVITY; RISK FACTOR; CASE CONTROL STUDY; CLINICAL TRIAL; COST OF ILLNESS; DRUG TOXICITY; ECONOMICS; FEMALE; MALE; MEDICATION ERROR; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS;

ADULT; AGED; CASE-CONTROL STUDIES; COST OF ILLNESS; DIRECT SERVICE COSTS; DRUG TOXICITY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICATION ERRORS; MIDDLE AGED; MODELS, ECONOMETRIC; NETHERLANDS; PATIENT ADMISSION; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79952669338     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.024     Document Type: Article

References (35)

1. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18, 820 patients. BMJ 2004;329:15-9. (Pubitemid 38869995)
2. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM; HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in The Netherlands. Arch Intern Med 2008;168:1890-6.
3. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997;277:307-11. (Pubitemid 27045011)
4. Hoonhout LH, de Bruijne MC, Wagner C, et al. Direct medical costs of adverse events in Dutch hospitals. BMC Health Serv Res 2009;9:27.
5. Patel KJ, Kedia MS, Bajpai D, et al. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol 2007;7:8.
6. Giesbers H. Hospital bed capacity 2003 [In Dutch: Beddencapaciteit ziekenhuizen 2003]. In: Volksgezondheid Toekomst Verkenning, Nationale Atlas Volksgezondheid. Bilthoven: RIVM, June 2006. Available from: www.zorgatlas.nlZorg\Ziekenhuiszorg\Algemene en academische ziekenhuizen\Aanbod. [Accessed December 2009.]
7. Van Hilten O, Mares A M H M. Figures in Health and Healthcare 2007 [In Dutch: Gezondheid en zorg in cijfers 2007]. Voorburg/Heerlen: CBS, 2007.
8. Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001;58:1126-32. (Pubitemid 32552897)
9. Rodriguez-Monguio R, Otero M, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003;21:623-50. (Pubitemid 36808215)
10. HM Treasury. Table 5.4 public sector current and capital expenditure on services by function, 2003-04 to 20070-08. [Online]. 2009 May 29, London, United Kingdom. Available from: www.hm-treasury.gov.uk/d/pesa2009-chapter5tables.xls. [Accessed December 2010.]
11. Wasserfallen J, Livio F, Buclin T, et al. Rate, type and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med 2001;12:442-7. (Pubitemid 32823524)
12. Dartnell J G A, Anderson RP, Chohan V, et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 1996;1634:659-62. (Pubitemid 26172599)
13. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988;84(Suppl. 2 A):20-4.
14. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian hospital-their severity and cost involved. Pharmacoepidemiol Drug Saf 2003;12:687-92. (Pubitemid 38028783)
15. Moore N, Lecointre D, Noblet C, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998;45:301-8. (Pubitemid 28081927)
16. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions, I: background, description, and instructions for use. JAMA 1979;242:623-31.
17. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27:538.
18. Oostenbrink JB, Bouwmans C A M, Koopmanschap MA, Rutten F F H. Dutch Guidelines for Pharmacoeconomic Research. [In Dutch: Handleiding voor kostenonderzoek; methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004]. Diemen: College voor zorgverzekeringen; 2004.
19. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 2002;20:443-54. (Pubitemid 34804173)
20. College voor zorgverzekeringen (CVZ). Richtlijnen voor farmaco-economisch onderzoek. Diemen: CVZ; 1999.
21. Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992;34:1005-10.
22. Jacob-Tacken KH, Koopmanschap MA, Meerding WJ, Severens JL. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 2005;14:435-43. (Pubitemid 40723852)
23. Koopmanschap MA, Rutten F F H, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.
24. Salem RB, Keane TM, Williams JG. Drug-related admissions to a Veterans' Administration psychiatric unit. Drug Intell Clin Pharm 1984;18:74-6. (Pubitemid 14215439)
25. Stewart RB, Sprinker PK, Adams JE. Drug-related admissions to an inpatient psychiatric unit. Am J Psychiatry 1980;137:1093-5. (Pubitemid 10048889)
26. Zermansky AG, Silcock J. Is medication review by primarycare pharmacists for older people cost effective? A narrative review of the literature, focusing on costs and benefits. Pharmacoeconomics 2009;27:11-24.
27. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine vs. Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719-26.
28. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole vs. Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34. (Pubitemid 28115091)
29. Brown TJ, Hooper L, Elliott RA, et al. A comparison of the cost-effectiveness of five strategies for the prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006;10:1-183.
30. Vonkeman HE, Braakman-Jansen LM, Klok RM, et al. Incremental cost effectiveness of proton pump inhibitors for the prevention of nonsteroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a casecontrol study. Arthritis Res Ther 2008;10:R144.
31. Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R. Monitoring blood glucose control in diabetes mellitus: a systematic review. Health Technol Assess 2000;4:1-93.
32. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000;320:1373-8. (Pubitemid 30261117)
33. Tunis SL, Minshall ME. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral antidiabetes drugs and with a recent history of monitoring: cost-effectiveness in the United States. Curr Med Res Opin 2010;26:151-62.
34. Miles CL, Fellowes D, Goodman ML, Wilkinson S. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2006;18: CD003448.
35. Mihaylov S, Stark C, McColl E, et al. Stepped treatment of older adults on laxatives. The STOOL trial. Health Technol Assess 2008;12: iii-iv, ix-139.